ReviewInternational journal of molecular sciences2026
Hemorheological Alterations as a Driver of Microangiopathy in Diabetic Kidney Disease-The Role of Erythrocyte.
Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic kidney disease (DKD) is a severe microvascular complication traditionally attributed to general metabolic derangement and genetic susceptibility. However, this classic pathophysiological approach overlooks the role of red blood cells in the development and the progression of the disease. Prolonged exposure to high blood glucose and oxidative stress compromises the cell's membrane architecture and ionic homeostasis, resulting in altered rheological properties. By synthesizing these molecular-to-rheological pathways, this review establishes a novel pathophysiological framework for understanding DKD, repositioning erythrocytes to a primary catalyst of renal injury and a highly sensitive target for early diagnostic intervention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.